IMTXW
Closed
Immatics Biotechnologies Gmbh
0.0006
-0.0046 (-88.46%)
Last Update: 30 Jun 2025 23:00:00
Yesterday: 0.0052
Day's Range: 0.0006 - 0.0148
Send
sign up or login to leave a comment!
When Written:
1.44
Immatics Biotechnologies GmbH is a clinical-stage biopharmaceutical company that specializes in the development of immunotherapies for cancer. The company was founded in 2000 and is headquartered in Tübingen, Germany, with additional offices in Houston, Texas, and Martinsried, Germany.
Immatics' proprietary technology platform, XPRESIDENT®, enables the identification of novel tumor-specific targets and the development of T-cell receptor-based immunotherapies. The company's lead product candidate, IMA101, is a T-cell receptor-based immunotherapy targeting the tumor antigen MAGE-A4 for the treatment of solid tumors.
Immatics has partnerships with several pharmaceutical companies, including Amgen, Celgene, and Genmab, to develop and commercialize its immunotherapies. The company has also raised over $200 million in funding from investors, including Wellington Management, AT Impf GmbH, and dievini Hopp BioTech holding GmbH & Co. KG.
As of 2021, Immatics has several ongoing clinical trials for its immunotherapies, including a phase II trial for IMA101 in non-small cell lung cancer and a phase I trial for IMA202 in solid tumors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Immatics' proprietary technology platform, XPRESIDENT®, enables the identification of novel tumor-specific targets and the development of T-cell receptor-based immunotherapies. The company's lead product candidate, IMA101, is a T-cell receptor-based immunotherapy targeting the tumor antigen MAGE-A4 for the treatment of solid tumors.
Immatics has partnerships with several pharmaceutical companies, including Amgen, Celgene, and Genmab, to develop and commercialize its immunotherapies. The company has also raised over $200 million in funding from investors, including Wellington Management, AT Impf GmbH, and dievini Hopp BioTech holding GmbH & Co. KG.
As of 2021, Immatics has several ongoing clinical trials for its immunotherapies, including a phase II trial for IMA101 in non-small cell lung cancer and a phase I trial for IMA202 in solid tumors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!